Literature DB >> 6194997

Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs.

A Somogyi, A McLean, B Heinzow.   

Abstract

The hypothesis that basic drugs can compete for active tubular secretion by the kidney was tested in six healthy volunteers by comparing the single dose pharmacokinetics of oral procainamide before and during a daily dose of cimetidine. The area under the procainamide plasma concentration-time curve was increased by cimetidine by an average of 35% from 27.0 +/- 0.3 micrograms/ml X h to 36.5 +/- 3.4 micrograms/ml X h. The elimination half-life increased from an harmonic mean of 2.92 to 3.68 h. The renal clearance of procainamide was reduced by cimetidine from 347 +/- 46 ml/min to 196 +/- 11 ml/min. All these results were statistically significant (p less than 0.016). The area under the plasma concentration-time curve for n-acetylprocainamide was increased by a mean of 25% by cimetidine due to a significant (p less than 0.016) reduction in renal clearance from 258 +/- 60 ml/min to 197 +/- 59 ml/min. The data suggests that cimetidine inhibits the tubular secretion of both procainamide and n-acetylprocainamide, and, if so, represents the first documented evidence for this type of drug interaction in man. The clinical implications from this study necessitate dosage adjustments of procainamide in patients being concomitantly treated with cimetidine. The interaction is pertinent not only for basic drugs that are cleared by the kidney, but also for metabolites of basic drugs and endogenous substances which require active transport into the lumen of the proximal tubule of the kidney for their elimination.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6194997     DOI: 10.1007/bf01037945

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  30 in total

1.  Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology.

Authors:  J S Dutcher; J M Strong; S V Lucas; W K Lee; A J Atkinson
Journal:  Clin Pharmacol Ther       Date:  1977-10       Impact factor: 6.875

2.  Procainamide dosage schedules, plasma concentrations, and clinical effects.

Authors:  J Koch-Weser; S W Klein
Journal:  JAMA       Date:  1971-03-01       Impact factor: 56.272

3.  Serum procainamide levels as therapeutic guides.

Authors:  J Koch-Weser
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

Review 4.  Drug interactions with cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

5.  Inhibition of renal creatinine secretion by cimetidine in humans.

Authors:  E Burgess; A Blair; K Krichman; R E Cutler
Journal:  Ren Physiol       Date:  1982

Review 6.  Therapeutic drug monitoring of antiarrhythmic agents.

Authors:  J E Brown; D G Shand
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

7.  Aging and renal clearance of procainamide and acetylprocainamide.

Authors:  M M Reidenberg; M Camacho; J Kluger; D E Drayer
Journal:  Clin Pharmacol Ther       Date:  1980-12       Impact factor: 6.875

8.  Ethanol-induced increase in procainamide acetylation in man.

Authors:  H Olsen; J Mørland
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

9.  Cimetidine and procainamide secretion by proximal tubules in vitro.

Authors:  T D McKinney; K V Speeg
Journal:  Am J Physiol       Date:  1982-06

10.  Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide.

Authors:  D M Roden; S B Reele; S B Higgins; G R Wilkinson; R F Smith; J A Oates; R L Woosley
Journal:  Am J Cardiol       Date:  1980-09       Impact factor: 2.778

View more
  41 in total

Review 1.  Clinical relevance of cimetidine drug interactions.

Authors:  A F Shinn
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

Review 2.  Effect of dietary protein on renal tubular clearance of drugs in humans.

Authors:  G D Park; R Spector; T M Kitt
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

Review 3.  Saturable pharmacokinetics in the renal excretion of drugs.

Authors:  C A van Ginneken; F G Russel
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

4.  Drug interactions through binding to cytochrome p 450: the experience with h2-receptor blocking agents.

Authors:  U Klotz; I W Reimann
Journal:  Pharm Res       Date:  1984-03       Impact factor: 4.200

Review 5.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 6.  Drug interactions at the renal level. Implications for drug development.

Authors:  P L Bonate; K Reith; S Weir
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

Review 7.  Adverse effects of class I antiarrhythmic drugs.

Authors:  J Caron; C Libersa
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

8.  Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide.

Authors:  U Klotz; P Arvela; B Rosenkranz
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 9.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

Review 10.  Renal effects of peptic ulcer therapy.

Authors:  E Burgess; D Muruve
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.